dc.contributor.author |
Hizal, M |
|
dc.contributor.author |
Bilgin, B |
|
dc.contributor.author |
Paksoy, N |
|
dc.contributor.author |
Acikgoz, O |
|
dc.contributor.author |
Sezer, A |
|
dc.contributor.author |
Gurbuz, M |
|
dc.contributor.author |
Ak, N |
|
dc.contributor.author |
Yucel, S |
|
dc.contributor.author |
Ayhan, M |
|
dc.contributor.author |
Erol, C |
|
dc.contributor.author |
Demirkiran, A |
|
dc.contributor.author |
Mandel, NM |
|
dc.contributor.author |
Shbair, A |
|
dc.contributor.author |
Gokmen, I |
|
dc.contributor.author |
Basoglu, T |
|
dc.contributor.author |
Paydas, S |
|
dc.contributor.author |
Demiray, AG |
|
dc.contributor.author |
Iriagac, Y |
|
dc.contributor.author |
Sakalar, T |
|
dc.contributor.author |
Zeynelgil, E |
|
dc.contributor.author |
Tatli, AM |
|
dc.contributor.author |
Bahceci, A |
|
dc.contributor.author |
Guven, DC |
|
dc.contributor.author |
Caner, B |
|
dc.contributor.author |
Can, A |
|
dc.contributor.author |
Gulmez, A |
|
dc.contributor.author |
Karakas, Y |
|
dc.contributor.author |
Yalcin, B |
|
dc.contributor.author |
Demirkazik, A |
|
dc.contributor.author |
Bilici, A |
|
dc.contributor.author |
Aydiner, A |
|
dc.contributor.author |
Yumuk, PF |
|
dc.contributor.author |
Sendur, MAN |
|
dc.date.accessioned |
2022-10-05T13:18:59Z |
|
dc.date.available |
2022-10-05T13:18:59Z |
|
dc.date.issued |
2022 |
|
dc.identifier.uri |
http://hdl.handle.net/11616/62691 |
|
dc.description.abstract |
Introduction Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after first-line EGFR-TKI therapy. In this multicenter study, we aimed to determine the real-life efficacy and safety of Osimertinib in pretreated advanced NSCLC patients with T790M mutation. Materials and methods This retrospective trial included advanced T790M-mutant pretreated NSCLC patients who received Osimertinib from 24 different centers in Turkey. Primary endpoint was time-to-treatment discontinuation (TTD). Secondary endpoints were objective response rate (ORR), overall survival (OS), and safety. Results Of 163 patients, 68.7% had EGFR exon 19 deletion and 22.7% had exon 21 L858R mutation. Osimertinib was given as second-line treatment in 96 patients (58.9%) and third-line in 48 patients (29.4%). After median of 13-month follow-up, median TTD was 21.6 months with an 82.2% ORR. Estimated median OS was 32.1 months. Grade 3-4 adverse events were seen in 11.7% of the patients. Conclusion Osimertinib is a highly effective option in second- or third-line treatment of NSCLC patients with T790M mutation, with a favorable safety profile. |
|
dc.description.abstract |
C1 [Hizal, Mutlu] Ankara City Hosp, Dept Med Oncol, Ankara, Turkey. |
|
dc.description.abstract |
[Bilgin, Burak; Yucel, Sebnem] Ataturk Chest Dis & Chest Surg Res & Educ Hosp, Dept Med Oncol, Ankara, Turkey. |
|
dc.description.abstract |
[Paksoy, Nail; Aydiner, Adnan] Istanbul Univ, Dept Med Oncol, Istanbul Fac Med, Istanbul, Turkey. |
|
dc.description.abstract |
[Acikgoz, Ozgur; Bilici, Ahmet] Medipol Univ, Dept Med Oncol, Fac Med, Istanbul, Turkey. |
|
dc.description.abstract |
[Sezer, Ahmet] Baskent Univ, Dept Med Oncol, Fac Med, Adana, Turkey. |
|
dc.description.abstract |
[Gurbuz, Mustafa; Demirkazik, Ahmet] Ankara Univ, Dept Med Oncol, Fac Med, Ankara, Turkey. |
|
dc.description.abstract |
[Ak, Naziye] Yozgat City Hosp, Dept Med Oncol, Yozgat, Turkey. |
|
dc.description.abstract |
[Ayhan, Murat] Kartal Lutfi Kirdar City Hosp, Dept Med Oncol, Istanbul, Turkey. |
|
dc.description.abstract |
[Erol, Cihan; Yalcin, Bulent; Sendur, Mehmet Ali Nahit] Yildirim Beyazit Univ, Dept Med Oncol, Fac Med, Ankara, Turkey. |
|
dc.description.abstract |
[Demirkiran, Aykut] Necmeddin Erbakan Univ, Meram Fac Med, Dept Med Oncol, Konya, Turkey. |
|
dc.description.abstract |
[Mandel, Nil Molinas] Amer Hosp, Dept Med Oncol, Istanbul, Turkey. |
|
dc.description.abstract |
[Shbair, Abdallah] Bezmialem Univ, Dept Med Oncol, Fac Med, Istanbul, Turkey. |
|
dc.description.abstract |
[Gokmen, Ivo] Trakya Univ, Dept Med Oncol, Fac Med, Edirne, Turkey. |
|
dc.description.abstract |
[Basoglu, Tugba; Yumuk, Perran Fulden] Marmara Univ, Div Med Oncol, Sch Med, Istanbul, Turkey. |
|
dc.description.abstract |
[Paydas, Semra] Cukurova Univ, Dept Med Oncol, Fac Med, Adana, Turkey. |
|
dc.description.abstract |
[Demiray, Atike Gokcen] Pamukkale Univ, Dept Med Oncol, Fac Med, Denizli, Turkey. |
|
dc.description.abstract |
[Iriagac, Yakup] Namik Kemal Univ, Dept Med Oncol, Fac Med, Tekirdag, Turkey. |
|
dc.description.abstract |
[Sakalar, Teoman] Necip Fazil City Hosp, Dept Med Oncol, Kahramanmaras, Turkey. |
|
dc.description.abstract |
[Zeynelgil, Esra] Diskapi Educ & Res Hosp, Dept Med Oncol, Ankara, Turkey. |
|
dc.description.abstract |
[Tatli, Ali Murat] Akdeniz Univ, Dept Med Oncol, Fac Med, Antalya, Turkey. |
|
dc.description.abstract |
[Bahceci, Aykut] Ersin Arslan Educ & Res Hosp, Dept Med Oncol, Gaziantep, Turkey. |
|
dc.description.abstract |
[Guven, Deniz Can] Hacettepe Univ, Dept Med Oncol, Fac Med, Ankara, Turkey. |
|
dc.description.abstract |
[Caner, Burcu] Uludag Univ, Dept Med Oncol, Fac Med, Bursa, Turkey. |
|
dc.description.abstract |
[Can, Alper] Istinye Univ, Dept Med Oncol, Fac Med, Istanbul, Turkey. |
|
dc.description.abstract |
[Gulmez, Ahmet] Inonu Univ, Dept Med Oncol, Fac Med, Malatya, Turkey. |
|
dc.description.abstract |
[Karakas, Yusuf] Bodrum Acibadem Hosp, Dept Med Oncol, Mugla, Turkey. |
|
dc.source |
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
|
dc.title |
The real-life efficacy and safety of osimertinib in pretreated advanced |
|
dc.title |
non-small cell lung cancer patients with T790M mutation: a Turkish |
|
dc.title |
Oncology Group Study |
|